Haoyunbang Secures Tens of Millions in Series B Funding, Files for IPO to Expand in Infertility Care

VCBeat has learned that Haoyunbang, a platform specializing in the vertical medical field of infertility treatment, has announced the completion of its tens-of-millions-yuan Series B financing round. The round was led by Chongshan Capital, with participation from four institutions: Puhua Capital, Sinovest Capital, and Gene Capital. With this round, Haoyunbang has secured three rounds of funding over the past three years, totaling nearly RMB 100 million.

Haoyunbang, established in 2014, is a one-stop fertility assistance platform dedicated to addressing infertility. It is committed to integrating domestic and international resources in the reproductive health sector to provide professional and reliable fertility solutions for women experiencing difficulties in conceiving or carrying a pregnancy to term, as well as those diagnosed with infertility. Leveraging its internet-based medical platform for infertility care, Haoyunbang connects key resources and critical links across the infertility service chain, actively establishing physical clinics and hospital partnerships to create a comprehensive online-to-offline closed-loop ecosystem.

According to the “Report on the Current Status of Infertility in China” released by the China Population Association in 2009, the incidence of infertility in China ranges from 12.5% to 15%, with more than 40 million affected individuals, meaning that one in every eight couples experiences infertility issues.

Hao Yun Bang CEO Huang Sen stated that users facing infertility are stratified: some can resolve their issues with minimal medical intervention, such as coital guidance or ultrasound-based ovulation monitoring; others require surgical treatment, while still others need assisted reproductive technology (ART) treatment.

Haoyunbang aims to leverage its online platform (disease course management and human consultants) to help users address minor issues, thereby minimizing detours.Preconception clinics address relatively severe conditions, particularly the treatment of specific subtypes of disorders; for more advanced cases, reproductive centers intervene using assisted reproductive technologies.Platform–Clinic–Reproductive Center–Overseas forms a relatively complete closed loop, with user trust running through this entire chain.

It is understood that,Haoyunbang has accumulated over 3 million users, connected with more than 10,000 reproductive specialists, and partnered with over 30 hospitals, including strategic collaborations with top-tier (Grade 3A) institutions such as the Reproductive Hospital Affiliated to Shandong University, Beijing Chaoyang Hospital, and Peking University People's Hospital.. In 2016, commercialization efforts were initiated, and break-even was achieved in October of the same year.

In 2017, two offline clinics were established, with the Beijing clinic officially opening on April 20. Additionally, Haoyunbang launched the Haoyun International brand, partnering with leading assisted reproductive technology institutions in the United States, Thailand, Cambodia, and other countries, and establishing overseas reproductive centers.

Huang Sen, CEO of Haoyunbang, stated that after three years in the industry, Haoyunbang is no longer defined simply as a pure internet company or a traditional brick-and-mortar enterprise. Instead, it is a company integrating the internet with healthcare, representing perhaps a new business model.

Compared with internet companies, Haoyunbang has gained in-depth understanding and established a strong presence in the physical healthcare sector, and will further expand its offline footprint by laying out clinics and hospitals; compared with traditional reproductive centers, it benefits from the support of an online platform and more multidimensional marketing capabilities based on online channels.

Mr. Lu Dongcheng, Founding Partner of Chongshan Capital, stated that Chongshan has been closely tracking the reproductive health industry for several years, noting China’s vast population and market foundation. The use of the internet as a platform to support preconception care and eugenics can significantly enhance efficiency. We anticipate that this market will receive substantial attention and benefit from more open policies in the future.

With greater resource support in this niche sector, Haoyunbang will continue to expand its competitive advantages and establish a decisive market position! The Haoyunbang team is highly resilient, combative, entrepreneurial, and compassionate; their venture is driven by the mission to help more people. Chongshan is willing to integrate resources with such an outstanding team and move forward side by side!

Wen Huisheng, Partner at Gene Capital, stated that in an era of deregulation regarding policies such as physicians’ multi-site practice and social capital participation in healthcare provision, internet platforms have the opportunity to extend into clinical care services and build integrated online-to-offline comprehensive healthcare platforms. We firmly maintain a positive outlook on and fully support the Haoyunbang team, looking forward to their continued creation of greater value for users and society at large.